Skip to content

Confidence in Gambling Disorder: The role of dopamine, incentives and cognitive flexibility

Confidence in Gambling Disorder: The role of dopamine, incentives and cognitive flexibility

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON20659
Enrollment
60
Registered
2021-03-23
Start date
2021-03-23
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gambling Disorder

Interventions

None listed

Sponsors

NWO Aspasia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: GD group: 1. DSM-5 diagnosis for Gambling Disorder (To ensure that we are including people who exhibit pathological gambling behaviour, also considered compulsive gambling, we decided to include people who actually received this diagnosis and will by definition exhibit abnormal behaviour). 2. No other psychiatric disorders 3. Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements 4. 20-55 years of age 5. Male HC group: 6. No current psychiatric diagnosis or history of addictions 7. Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements 8. 20-55 years of age 9. Male

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: All groups: 1. Current major depressive disorder, bipolar disorder, psychotic disorder, alcohol or substance dependence, or any cognitive disorder as assessed with the MINI neurological disorders section 2. IQ below 80 3. Insufficient command of the Dutch language 4. MRI contraindications such as metal implants or claustrophobia 5. Use of dopaminergic ADHD medication, 6. Endocrinological disorders or regular use of corticosteroids 7. History of neurological treatment 8. History of epilepsy 9. History of autonomic failure 10. History of clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic or pulmonary disease 11. Claustrophobia 12. Use of other psychotropic medication, or of recreational drugs over a period of 72 hours prior to each test session, and use of alcohol within the last 24 hours before measurement 13. Irregular sleep/wake rhythms (e.g. regular nightshifts) 14. Use of MAO inhibitor, anaesthetic, anti-depressant or anti-psychotic drugs within the week prior to the start of the study 15. History of prescribed medication within the last month prior to the start of the study Exclusion criteria directly related to PET scanning for both groups: 1. Participation in a scientific examination where radiation was used, in the last year 2. Positive urine drug screen on the day of the PET scan. Participants will be tested on cannabis, amphetamine, XTC, cocaine and opiates. Only recent cannabis use will be accepted 3. Lactose intolerance (entacapone and carbidopa capsules contain lactose)

Design outcomes

Primary

MeasureTime frame
Dopamine synthesis capacity (Ki values)

Secondary

MeasureTime frame
Confidence levels in symptom-relevant context & Cognitive flexibility in reversal learning & nMRI signal & Gambling symptom severity

Contacts

Public ContactMonja Hoven

Amsterdam UMC locatie AMC

m.hoven@amsterdamumc.nl020-8914556

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)